RJFSA
DNA icon

Raymond James Financial Services Advisors’s Ginkgo Bioworks DNA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,270
Closed -$30.4K – 3474
2024
Q2 		$30.4K Sell
2,270
-1,106
-33% -$33K ﹤0.01% 3327
2024
Q1 		$157K Buy
3,376
+306
+10% +$15.8K ﹤0.01% 3155
2023
Q4 		$208K Sell
3,070
-28
-0.9% -$1.71K ﹤0.01% 2968
2023
Q3 		$224K Buy
3,098
+1,259
+68% +$101K ﹤0.01% 2858
2023
Q2 		$137K Buy
1,839
+35
+2% +$2.07K ﹤0.01% 3013
2023
Q1 		$96K Sell
1,804
-266
-13% -$16.9K ﹤0.01% 3058
2022
Q4 		$140K Sell
2,070
-2,113
-51% -$194K ﹤0.01% 2952
2022
Q3 		$522K Buy
4,183
+3,354
+405% +$400K ﹤0.01% 2222
2022
Q2 		$79K Buy
829
+177
+27% +$21.6K ﹤0.01% 3046
2022
Q1 		$105K Buy
652
+349
+115% +$67.9K ﹤0.01% 3106
2021
Q4 		$101K Sell
303
-134
-31% -$63.7K ﹤0.01% 3121
2021
Q3 		$203K Buy
+437
New +$213K ﹤0.01% 2971

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Raymond James Financial Services Advisors's DNA Position: Q3 2024 in Review

Raymond James Financial Services Advisors sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 2,270 shares — an estimated $30.4K sold.

Raymond James Financial Services Advisors first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $522K in Q3 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Raymond James Financial Services Advisors reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 2,270 Ginkgo Bioworks shares in Q3 2024, an estimated $30.4K.
  • Raymond James Financial Services Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Raymond James Financial Services Advisors's Ginkgo Bioworks position peaked at $522K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.